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doi:10.1Objective: A heightened inflammatory response occurs after cardiac surgery. The perioperative use of gluco-
corticoids has been advocated as a method to improve postoperative outcomes. Randomized prospective studies
to quantify the effect of methylprednisolone on perioperative outcomes in neonatal cardiac surgery have not
been performed. We sought to determine whether preoperative methylprednisolone would improve postopera-
tive recovery in neonates requiring cardiac surgery.
Methods:Neonates scheduled for cardiac surgery were randomly assigned to receive either 2-dose (8 hours pre-
operatively and operatively, n ¼ 39) or single-dose (operatively, n ¼ 37) methylprednisolone (30 mg/kg per
dose) in a prospective double-blind trial. The primary outcome was the incidence of low cardiac output syn-
drome (standardized score) or death 36 hours postoperatively. Secondary outcomes were death at 30 days,
interleukin-6 levels, inotropic score, fluid balance, serum creatinine, and intensive care unit and hospital stay.
Results: Preoperative plasma levels of the inflammatory cytokine interleukin-6 were reduced by 2-fold
(P<.001) in the 2-dose methylprednisolone group, consistent with the anti-inflammatory effects of methylpred-
nisolone. However, the incidence of low cardiac output syndrome was 46% (17/37) in the single-dose and 38%
(15/39) in the 2-dose methylprednisolone groups (P ¼ .51). Two-dose methylprednisolone was associated with
a higher serum creatinine (0.61 0.18 mg/dL vs 0.53 0.12 mg/dL, P¼ .03) and poorer postoperative diuresis
(96 49 mL, P¼ .05). Inotropic requirement, duration of mechanical ventilation, intensive care unit, and hos-
pital stay did not differ between the 2 groups.
Conclusions: Combined preoperative and intraoperative use of glucocorticoids in neonatal cardiac surgery does
not favorably affect early clinical outcomes and may exacerbate perioperative renal dysfunction. (J Thorac
Cardiovasc Surg 2011;142:1523-9)MThe performance of corrective or palliative cardiac surgery
for congenital cardiac defects can be associated with a com-
plex postoperative course. This is particularly truewhen these
cardiac procedures are necessary in neonates in whom an in-
creased risk of morbidity and mortality is encountered in the
early postoperative period. In adults and older pediatric pa-
tients, it has been demonstrated that one of the ubiquitous
consequences of cardiopulmonary bypass (CPB) is a height-
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Pstate has been postulated to negatively affect cardiac
function and hemodynamic status, leading to postoperative
morbidity, such as low cardiac output syndrome (LCOS),
shifts in fluid balance, and increased need for mechanical
and pharmacologic support.3 As a result, the empirical use
of prophylactic anti-inflammatory therapy, primarily through
the use of glucocorticoids, has become a common practice in
pediatric cardiac surgery.4,5 Outcomes data regarding the use
of glucocorticoids have been variable, the dosing regimens
and protocols have not been uniform, and the evaluation of
preoperative steroid treatment in neonates has not been
specifically examined.4-12 Accordingly, the overall goal of
this study was to perform a prospective, randomized study
to test the hypothesis that preoperative glucocorticoid
therapy, added to standard intraoperative administration,
would improve early postoperative outcomes and indices of
inflammation in neonates undergoing cardiac operations
requiring CPB.MATERIALS AND METHODS
Rationale and Study Overview
Although the optimal type and dose of glucocorticoid for use in the con-
text of CPB remain to be established, the most commonly used agent is
methylprednisolone (MP).4 MP has been used in small pediatric cardiacdiovascular Surgery c Volume 142, Number 6 1523
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
ICU ¼ intensive care unit
IL ¼ interleukin
LCOS ¼ low cardiac output syndrome
MP ¼ methylprednisolone
WBC ¼ white blood cell
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Msurgery series and by the Pediatric Heart Network in a randomized placebo-
controlled clinical trial of Kawasaki disease treatment in children.6,13 By
extrapolating from these studies, intravenous MP at 30 mg/kg of body
weight was chosen for use. The timing of the preoperative dose was
chosen to optimize the potential effect based on institutional experience,
because pharmacokinetic data have not been reported specifically in
neonates. The use of some type of intraoperative steroids during neonatal
cardiac surgery is widespread.4,5 In light of the presumed beneficial
effects demonstrated in both animal and small pediatric studies, and
given the widespread use of MP, we considered it inappropriate to
randomize neonates to a completely placebo control group.4,6,12
Patient Selection, Enrollment, and Randomization
All inpatient neonates (aged 30 days) whowere scheduled to undergo
cardiac surgery involving CPB from July 2007 to July 2009 were eligible
for this study (ClinicalTrials.gov Identifier: NCT00934843). Exclusion cri-
teria included prematurity (defined as  36 weeks gestational age) at the
time of surgery, treatment with steroids in the 2 weeks before surgery, sus-
pected infection that would contraindicate steroid use (eg, herpes), known
hypersensitivity toMP or other contraindication to steroid therapy (eg, gas-
trointestinal bleeding), preoperative use of mechanical circulatory support
or active resuscitation at the time of proposed randomization, and inability
to begin the preoperative study drug at least 8 hours before surgery. The
study was approved by the institutional review board, and informed written
consent was obtained from the parent or legal guardian. Patients were strat-
ified on the basis of a planned palliative or corrective procedure and then
randomized by the investigational pharmacy to 1 of 2 study groups: preop-
erative placebo and intraoperative MP (single-dose group) or preoperative
and intraoperative MP (2-dose group). All investigation and clinical site
personnel were blinded to the treatment allocation until the close of the
study.
Perioperative Management
Preoperative management followed the general principle of reasonable
avoidance of mechanical ventilation and inotropic medications. Study
medication, 30 mg/kg MP or a similar volume of normal saline, was in-
fused over a 1-hour period 8 hours before scheduled CPB. In the operating
room, general anesthesia was attained with narcotics, muscle paralysis, and
inhaled anesthetic. The CPB prime included 30mg/kg ofMP in all patients.
A heparin-bonded circuit was used for circulatory support. Full-flow by-
pass at mild hypothermia (32C) or low-flow bypass at deep hypothermia
(20C–25C) was used. Cold-blood cardioplegia was given at 20-minute
intervals during periods of aortic crossclamping. Deep hypothermic circu-
latory arrest was performed at 18C when necessary. Acid-base manage-
ment was by a pH stat strategy. Conventional and modified ultrafiltration
were used in all cases. Leukocyte depletion filters were not used in any pa-
tient. Aprotinin was used in all patients except 1 beforeMay 2008 and in no
patient subsequently because of its unavailability. Delayed sternal closure
was used in all patients undergoing a Norwood procedure and in other op-
erations as needed. All patients were managed postoperatively in a dedi-
cated pediatric cardiac intensive care unit (ICU). Unless significant1524 The Journal of Thoracic and Cardiovascular Surhypotension or renal dysfunction was present, milrinone was used at
a dose of 0.5 mg/kg/min.
Primary and Secondary Response Variables
The primary end point was the incidence of death or LCOS at 36 hours
from admission to the ICU after surgery. The presence of LCOS was de-
fined by the same definition used in the PRIMACORP study,3 specifically,
if there were clinical signs and symptoms of low cardiac output (eg, tachy-
cardia, oliguria, cold extremities, cardiac arrest) that required 1 or more of
the following interventions: mechanical circulatory support, the escalation
of existing pharmacologic circulatory support to more than 100% over
baseline, or the initiation of new pharmacologic circulatory support. The
determination of LCOS was made by 2 independent reviewers (EMG,
AMA) and then agreed on between both reviewers before unblinding.
Secondary end points included inotropic score, urine output, and total fluid
balance over the first 36 hours postoperatively, and the incidence of death
between 36 hours and 30 days postoperatively. The inotropic scorewas cal-
culated by the equation using drug dosages in micrograms/kilograms/min-
ute (dopamineþdobutamine)þ(milrinone310)þ(epinephrine3100) and
recorded on arrival to the ICU, 4, 8, 12, 24, and 36 hours postopera-
tively.14,15 The highest score during this timeframe was also recorded.
Secondary end points also included the duration of postoperative
mechanical ventilation and ICU and hospital stay. Markers of
inflammation, including white blood cell (WBC) count and the plasma
level of the proinflammatory cytokine interleukin (IL)-6, were compared
between groups. WBC was determined immediately preoperatively,
immediately postoperatively, and at 36 hours postoperatively. Plasma
samples collected before preoperative placebo/MP treatment (8 hours
preoperatively), immediately preoperatively, on completion of modified
ultrafiltration, and at 4, 12, and 24 hours postoperatively were subjected
to multiplex analysis for IL-6.
Sample Size Estimates
The PRIMACORP study, from which the criteria of LCOSwere derived
for the present study,3 reported that milrinone reduced LCOS in neonates
by approximately 16% (23% vs 7%).16 In a prior series of children under-
going cardiac surgery and CPB, a combined preoperative and operative MP
was reported to reduce the incidence of LCOS by 26% (40% vs 14%).6
The current study was designed with an anticipated enrollment of 87 pa-
tients per treatment arm to achieve a statistical power of 80% (1-b) while
controlling type I error at 0.05 (a) using a more conservative estimate of
LCOS rate of 33% in the single-dose MP group and an incidence of
LCOS of 15% in the 2-dose MP group. After recruiting for 25 months,
76 patients had been assessed for the outcome of interest. The aggregate
incidence rate of LCOS was higher than anticipated at 42% (32/76 vs an
anticipated 24%). After unblinding, the effect size was in the direction hy-
pothesized, but this difference was only 7.5%. At the time of unblinding,
the conditional power to detect the hypothesized difference of 18% was
calculated to determine the futility of continuing the study.17 The condi-
tional power was determined to be 8.3% using Cytel East5 software (ver-
sion 5; Cytel Inc, Cambridge, Mass). This low (conditional) probability of
rejecting the null hypothesis provided adequate evidence against finding
a significant effect and led to the suspension of further patient enrollment.18
Data Analysis
The continuous preoperative and postoperative clinical characteristics
are presented as mean  standard deviation. For the categoric variables,
the percent incidence is presented. Treatment group comparisons for con-
tinuous variables were performed using aWilcoxon rank-sum test, and cat-
egoric variables were compared using a Pearson’s chi-square test (Fisher
exact test where appropriate). Because of the high incidence of LCOS
and the prospective nature of the study, the outcome was subjected to uni-
variate and multivariable risk regression with robust error variancegery c December 2011
Graham et al Perioperative Managementestimates to determine unadjusted and adjusted relative risk ratios. Maxi-
mum likelihood methods were implemented to estimate the parameters us-
ing a log-linear model in SAS proc genmod using Poisson regression
modeling with robust error variance estimates.19 Analysis of variance/
covariance models was used to test both unadjusted and multivariable re-
lationships between treatment groups for blood chemistries and diuresis.
A repeated-measures analysis of variance framework was used for longitu-
dinal analysis of inotrope score, plasma creatinine, WBC, and the loga-
rithm of IL-6. To identify potential confounding variables, a variable was
considered a relevant covariate and added into the model with a P value
of .15 or less. Potential confounding variables included race, gender, sys-
tolic blood pressure, weight at time of surgery, and gestational age. During
the execution of this study, the antifibrinolytic aprotinin was discontinued
from clinical use and thereforewas included in all adjusted models. Model-
based estimates are reported as the mean standard error. Statistical anal-
yses were performed with SAS (version 9.1.3; SAS Institute, Inc, Cary,
NC). All significance tests are 2 tailed, and no correction for multiple test-
ing has been applied to reported P values.RESULTS
Preoperative Demographics and Intraoperative
Variables
Enrollment and outcomes are shown in Figure 1. A total
of 76 patients were randomly assigned to either preopera-
tive placebo and intraoperative MP (single-dose MP group,
n ¼ 37; 49%) or preoperative and intraoperative MP
(2-dose MP group, n ¼ 39; 51%) protocol. Patient demo-97 Neonates screened 
18 Ineligible  
10  Did not match  
inclusion/exclusion criteria 
3  Language barrier  
l d d i f d t prec  u e   n  orme  consen 
5  Unable to consent family  
member 
1 Declined participation 
78 Randomized 
41 Randomly assigned to     
receive preoperative  
steroid 
40 Received intervention as  
37 Randomly assigned to     
receive preoperative  
placebo 
assigned 
1 Did not receive intervention  
assigned expired prior to  
intervention 
37 Received intervention 
as assigned 
0 Discontinued intervention 
37 Included in primary analysis 
1 Discontinued intervention  
surgery plan changed and  
did not re uire CPB q 
39 Included in primary analysis 
FIGURE 1. Flow of patients through the trial. CPB, Cardiopulmonary
bypass.
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Mgraphics, cardiac diagnoses, and clinical characteristics
are summarized in Table 1. The groups were well balanced
with respect to gender, cardiac malformation, and planned
surgical procedure. The gestational age was slightly older
in the 2-dose MP group, but the ages and weight at the
time of surgery were similar. Intra- and perioperative pa-
rameters are shown in Table 2. The overall CPB time, cross-
clamp time, use of deep hypothermic circulatory arrest, and
immediate postoperative procedures were similar between
the 2 MP treatment groups.
Postoperative Outcomes: Primary Response
Variables
The incidence of LCOS was 46% (17/37) in the single-
dose MP group and 38% (15/39) in the 2-dose MP group,
with no difference between groups. By using an unadjusted
univariate risk computation, the relative risk ratio for the
2-dose MP group was 0.84 (95% confidence interval,
0.49–1.42; P ¼ .51), indicating no reduction in the risk of
LCOS with this treatment strategy. Although the treatment
groups were well balanced with respect to potential con-
founding variables, an adjusted analysis was performed
including previouslymentioned covariates. The adjusted rel-
ative risk was computed for the 2-dose MP group, yielding
a relative risk of 0.78 (95% confidence interval, 0.45–1.33;
P ¼ .35).
Overall 30-day survival was 98.7%. There were no
deaths in the first 36 hours postoperatively in either group.
There was a single death between 36 hours and 30 days
postoperatively in the single-dose MP group, secondary to
gram-negative sepsis 19 days after a central shunt and pul-
monary arterioplasty for tetralogy of Fallot with pulmonary
atresia. Other clinical response variables, such as duration
of mechanical ventilation, ICU time, and hospital stay,
were similar between the 2 different MP treatment groups
(Table 3).
Perioperative Outcomes and Laboratory Values
The inotrope score as a function of time postoperatively
is summarized in Figure 2. Inotropic score increased in
a predictable manner early postoperatively and decreased
as a function of time, with no differences between groups
(adjusted F1,70¼ 0.03; P¼ .86). Clinical outcome variables
are summarized in Table 3. The highest plasma lactate value
recorded in the postoperative period was higher in the 2-
dose MP group (Table 3). Similarly, plasma creatinine
was higher in the immediate postoperative period in the
2-dose MP group: 0.61  0.18 mg/dL compared with
0.53  0.12 mg/dL (P ¼ .03, Figure 2). Total fluid admin-
istration and outputs for the first 36 hours postoperative are
described in Table 3. When adjusted for fluid intake and in-
termittent bolus versus continuous furosemide administra-
tion, the between-group differential in fluid output (101
 50 mL, P ¼ .047) and urine output (96  49 mL,diovascular Surgery c Volume 142, Number 6 1525
TABLE 1. Preoperative demographics in neonatal patients undergoing cardiac surgery randomized tosingle-or 2-dose methylprednisolone
strategy
MP single-dose
n ¼ 37
MP 2-dose
n ¼ 39 P value
Age/gender
Gestational age at birth (wk) 38.3  1.4 38.9  1.2 .08
Gestational age at surgery (wk) 39.5  1.4 40.2  1.6 .04
Age at surgery (d) 8.2  5.0 9.4  6.3 .34
Age  7 d, n (%) 27 (73%) 23 (59%) .30
Weight at surgery (kg) 3.1  0.5 3.3  0.5 .11
Prenatal diagnosis, n (%) 15 (41%) 18 (46%) .62
Male, n (%) 19 (51%) 20 (51%) .99
Creatinine (mg/dL) 0.51  0.15 0.56  0.21 .25
Diagnosis Operative procedure
Corrective procedure 21 (57%) 22 (56%) P ¼ .84
Aortic arch hypoplasia with VSD 5 5 Aortic arch repair, VSD closure
Tetralogy of Fallot 2 2 Complete repair with transannular patch
Transposition of the great arteries  VSD 11 10 Arterial switch  VSD closure
Truncus arteriosus 1 3 Complete repair
Other biventricular repair 2 2
Palliative procedure 16 (43%) 17 (44%) P ¼ .84
Hypoplastic left heart syndrome 6 8 Norwood procedure
Other single ventricle lesions 8 7 Norwood, mBTS, RV-PA shunt, pulmonary
artery operation
Pulmonary atresia with intact ventricular septum 0 2 RVOT patch, mBTS
Tetralogy of Fallot with pulmonary atresia 2 0 mBTS and pulmonary arterioplasty
VSD, Ventricular septal defect; mBTS, modified Blalock–Taussig shunt; RV-PA, right ventricle to pulmonary artery; MP, methylprednisolone; RVOT, right ventricular outflow
tract. Data are reported as mean  standard deviation. Data are reported as number (%). Single-dose: 30 mg/kg MP in CPB prime; 2-dose: 30 mg/kg preoperative and 30
mg/kg MP in CPB prime.
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MP ¼ .052) was slightly worse in the 2-dose MP group. IL-6
values before randomization and MP treatment were equiv-
alent between groups (Figure 2), but were lower preopera-
tively in the 2-dose MP group (adjusted F1,65 ¼ 45.0;
P<.001), consistent with the anti-inflammatory effects of
this pharmacologic protocol. Plasma IL-6 increased equiv-
alently in both groups by approximately 2-fold in the post-
operative period (steroid effect: F1,65 ¼ 0.10; P ¼ .909)
regardless of group assignment and consistent with past re-TABLE 2. Intraoperative and perioperative parameters in neonatal
patients undergoing cardiac surgery randomized to single- or 2-dose
methylprednisolone strategy
MP single-dose
n ¼ 37
MP 2-dose
n ¼ 39
P
value
CPB time (min) 168  71 156  39 .62
Aortic crossclamp time (min) 71  36 67  28 .83
Use of DHCA, n (%) 14 (38%) 17 (44%) .61
DHCA time (min) 23  14 21  10 .64
Modified ultrafiltration time (min) 12  2 13  3 .13
Aprotinin administration, n (%) 18 (49%) 16 (41%) .50
Delayed sternal closure, n (%) 20 (54%) 18 (46%) .49
MP, Methylprednisolone; CPB, cardiopulmonary bypass; DHCA, deep hypothermic
circulatory arrest. Data are reported as mean  standard deviation. Single-dose: 30
mg/kg MP in CPB prime; 2-dose: 30 mg/kg preoperative and 30 mg/kg MP in
CPB prime.
1526 The Journal of Thoracic and Cardiovascular Surports.6,7,20 The WBC count was similar between groups in
the preoperative period (11.9  0.5 3 103/mm3 in the
single-dose MP group vs 10.7  0.6 3 103/mm3 in the
2-dose MP group, P ¼ .14). However, the WBC count in
the immediate postoperative period was significantly higher
in the 2-dose MP group (7.8  0.5 3 103/mm3 in the
single-dose MP group vs 9.5  0.6 3 103/mm3 in the 2-
dose MP group, P ¼ .04). At later postoperative periods,
the WBC count was similar between groups.DISCUSSION
The fundamental premise of this study was that if gluco-
corticoids impart a protective effect in the context of neona-
tal cardiac surgery, then it would be expected that the 2-dose
MP protocol would translate into improved early postoper-
ative outcomes. The prospective randomization yielded
a balanced set of patients in each treatment arm and thereby
provided control for a number of potentially confounding
variables. The unique findings from the present study are
3-fold. First, the absolute incidence and relative risk for
LCOS were not different between the MP dosing strategies.
Second, plasma creatinine, lactate level, and fluid balance
were actually worse in the 2-dose MP group, with no differ-
ences in other postoperative outcome variables between the
MP dosing strategies. Third, although the 2-dose MPgery c December 2011
TABLE 3. Univariate postoperative outcomes in neonatal patients
undergoing cardiac surgery randomized to single- or 2-dose
methylprednisolone strategy
MP
single-dose
n ¼ 37
MP
2-dose
n ¼ 39
P
value
Mechanical cardiac support,
n (%)
3 (8%) 1 (3%) .35
Mechanical ventilation (d) 5.8  7.9 6.8  9.5 .21
ICU stay (d) 11.0  18.5 10.8  12.8 .19
Hospital stay (d) 23  25 22  15 .34
Total fluid in at 36 h (mL) 575  145 586  156 .77
Total fluid out at 36 h (mL) 600  250 558  203 .43
Total urine output at
36 h (mL)
498  227 453  213 .38
C-reactive protein at 36 h 6.2  3.6 6.3  4.9 .89
Highest inotropic score 14.4  3.6 15.0  3.9 .43
Highest lactate (mmol/L) 3.8  2.4 5.2  3.5 .05
Highest temperature in first
36 h (C)
37.5  0.3 37.4  0.4 .70
Highest glucose 145  27 167  54 .12
Insulin drip, n (%) 0 3 (8%) .24
Infection, n (%) 5 (14%) 5 (13%) .96
Poor wound healing, n (%) 1 (3%) 5 (13%) .20
Additional postoperative
steroids, n (%)
6 (16%) 8 (21%) .85
Thyroid supplementation,
n (%)
8 (22%) 11 (28%) .51
MP,Methylprednisolone; ICU, intensive care unit. Data are reported as mean stan-
dard deviation.
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Mprotocol reduced preoperative cytokine levels, consistent
with an anti-inflammatory effect, this effect did not persist
into the postoperative period.
There is widespread use of perioperative glucocorticoid
administration in pediatric cardiac surgery, with 80% to
97% of centers using some form of glucocorticoid
therapy.4,5 However, the type of glucocorticoid and the
dosing and timing of administration are highly variable,
reinforcing the lack of convincing data to guide
therapeutic administration. In the largest pediatric study,
Pasquali and colleagues21 used the Pediatric Health Infor-
mation Systems Database to evaluate the outcomes of cor-
ticosteroids in children aged 0 to 18 years undergoing
congenital heart operations. Data from 46,730 patients
were included, 54% of whom received corticosteroids.
Multivariable analysis found no difference in postoperative
mortality between corticosteroid recipients and nonreci-
pients. Corticosteroids were associated with longer length
of stay, greater infection, and greater use of insulin. There
was no difference in duration of mechanical ventilation,
similar to the present study. In a subanalysis of 10,018 ne-
onates, corticosteroids were associated with significantly
longer postoperative ICU length of stay and greater use of
insulin. Although Pasquali and colleagues’ study has the in-The Journal of Thoracic and Carherent limitations of any observational study using a large
database, and the authors were unable to evaluate the impact
of different dosing regimens or exact timing or corticoste-
roid administration in relation to surgery, it is in agreement
with the current prospective randomized study.
Few controlled trials of glucocorticoids in the setting of
CPB in pediatrics can be found. Bronicki and colleagues7
randomized 29 children (mean age of 28 months) to receive
dexamethasone (1 mg/kg, n ¼ 15) or placebo (n ¼ 14) 1
hour before CPB. Both groups demonstrated a significant
elevation in IL-6 after CPB, similar to our findings. How-
ever, dexamethasone-treated patients had a blunted IL-6 re-
sponse when compared with placebo-treated patients. This
corresponded to an improvement in renal function (defined
as the number of patients whose postoperative creatinine
level increased 0.2 mg/dL above baseline) and respiratory
function, resulting in shorter durations of mechanical venti-
lation and ICU stay in the treatment group. Despite blinded
randomization, there may have been more complex diagno-
ses and operations in the placebo group. The improvement
in renal function is in contrast with our findings of an ele-
vated postoperative creatinine and worse diuresis and fluid
balance in the 2-dose MP group. Although MP is a potent
glucocorticoid, it does have some mineralocorticoid activ-
ity. The high doses used in the current study may explain
the decreased urine output and worse fluid balance in pa-
tients receiving 2-dose MP.
Lindberg and colleagues9 randomized 40 patients weigh-
ing more than 10 kg (mean age of 52 months) to receive
dexamethasone (1 mg/kg, n¼ 20) or placebo (n ¼ 20) after
the induction of anesthesia. C-reactive protein, as a marker
of inflammation, was lower in the treatment group on the
first postoperative day. Contrary to the findings of Bronicki
and colleagues,7 there were no significant differences in
clinical outcomes between treatment groups.
Schroeder and associates6 randomized 29 children (mean
age 4months) toMP (30 mg/kg, n¼ 15) or placebo (n¼ 14)
4 hours before CPB. As in our study, MP (30 mg/kg) was
administered in the pump prime in all patients. Serum IL-
6 was lower immediately and 4 hours after CPB in the com-
bined MP compared with the intraoperative only group, but
equally elevated in both groups by 24 hours. A lower core
body temperature, reduced fluid requirements, and im-
proved oxygen delivery were found in the combined ther-
apy group. Trends toward shorter ICU stay (P ¼ .07) and
incidence of LCOS (P ¼ .11) were found in the combined
treatment group. However, similar to our findings, there
were no differences in duration of mechanical ventilation
or inotropic requirements between groups.
Consistent with the findings of the present study, a recent
meta-analysis (including the previously mentioned studies)
failed to demonstrate any benefit in clinical outcomes with
glucocorticoid administration.10 Only 2 of the studies in-
cluded any neonates. Unique to the current study is thediovascular Surgery c Volume 142, Number 6 1527
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FIGURE 2. Perioperative outcomes. A, Inotrope score was computed
postoperatively in both the single- and 2-doseMP groups. There was an ex-
pected increase in inotrope score with respect to time (F5,70 ¼ 12.3,
P<.001). Although there was a slight reduction in inotrope score in the
2-dose MP group at 4 hours postoperatively, this did not reach statistical
significance (P ¼ .08). At later postoperative time points, inotrope score
was virtually equivalent between groups. B, Plasma creatinine values ob-
tained preoperatively, immediately postoperatively, and at 36 hours postop-
eratively for the single- and 2-dose MP groups. Plasma creatinine was
significantly higher in the 2-dose MP group immediately postoperatively
(*P ¼ .03). C, The proinflammatory cytokine IL-6 was measured before
=
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Msole inclusion of neonates, resulting in the inclusion of com-
plex corrective and palliative operations and the potential
increased morbidity associated with them. By combining
the other studies, there were only 7 of 128 patients who un-
derwent a palliative procedure (either complete or superior
cavopulmonary connection). Considered in total, the past
studies and the present study call into question the overall
utility of perioperative steroids in pediatric cardiac surgery.
Study Limitations
Limitations of the current study include the lack of a true
placebo group. Thus, recommendations for or against intra-
operative MP cannot be made. The widespread use of MP
and our decision to exclude a placebo arm were further con-
firmed in the recently published trial comparing shunt types
used in Norwood surgery.22 Of the 549 patients undergoing
the surgery, 498 (91%) received some type of steroid during
the surgery (Pediatric Heart Network, unpublished data,
2010). Although this study was more than 90% powered
to detected a difference in the primary outcome of LCOS,
it may have been inadequately powered to detected subtle
differences in other clinical outcomes. This, however, seems
unlikely given the almost identical important clinical out-
comes, such as inotropic score, duration of mechanical ven-
tilation, ICU, and hospital stay. The results of our trial do not
preclude the efficacy of other glucocorticoid regimens.
CONCLUSIONS
In the largest pediatric and only exclusively neonatal ran-
domized trial comparing the efficacy of preoperative gluco-
corticoid therapy with intraoperative glucocorticoid therapy
alone for neonates undergoing corrective and palliative car-
diac operations requiring CPB, our data do not provide sup-
port for the addition of a preoperative dose of MP to
a standard intraoperative dose alone. Although preoperative
dosing was associated with an improvement in preoperative
inflammatory markers, this did not correlate with improved
clinical outcomes. To the contrary, preoperative MP dosing
was associated with a higher immediate postoperative se-
rum creatinine level and worse diuresis and fluid balance
over the first 36 hours postoperatively. In light of these find-
ings, the routine use of preoperative glucocorticoids inrandomization to the MP protocol (pre-MP), immediately preoperatively,
immediately following modified ultrafiltration, and at 4, 12, and 24 hours
postoperatively. The 2-dose MP group, in whichMP was administered pre-
operatively and intraoperatively, resulted in a significant reduction in IL-6
values in the immediate preoperative period, consistent with an anti-
inflammatory effect (*P<.001). In the postoperative period, plasma IL-6
values significantly increased (F3,66 ¼ 34.7, P<.001), with no difference
between the single- and 2-dose MP groups. All data are presented as
mean standard error of the mean.MP,Methylprednisolone; IVMP, intra-
venous methylprednisolone; IL-6, interleukin-6.
gery c December 2011
Graham et al Perioperative Managementneonatal cardiac surgery needs to be reconsidered. A ran-
domized trial comparing intraoperative glucocorticoid to
placebo is indicated.References
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